OXidative stress and the production of intracellular reactive oxygen species (ROS), such as superoxide (O$_2^-$), hydrogen peroxide (H$_2$O$_2$), and hydroxyl radical (OH$^-$), have been implicated in the pathogenesis of cardiovascular disease, in part by promoting vascular smooth muscle proliferation.$^{1-4}$ Within the vessel wall, ROS are generated by several mechanisms, including vascular NAD(P)H oxidases.$^{5-6}$ ROS formation can be stimulated by mechanical stress, environmental factors, platelet derived growth factor (PDGF), angiotensin II (Ang II), and low density lipoproteins.$^{7-9}$ Because many risk factors for coronary artery disease such as hyperlipidaemia, hypertension, diabetes, and smoking increase production of ROS, it has been suggested that changes in vessel redox state are a common pathway involved in the pathogenesis of atherosclerosis and vascular injury.$^{1,2,10}$

Several key findings support the concept that ROS contribute to vascular diseases through effects on vascular smooth muscle cells (VSMC). Initial studies in our laboratory demonstrated that ROS stimulate cultured VSMC proliferation and activate intracellular kinases such as mitogen activated protein kinases (MAPK) which are associated with proto-oncogene expression and cell growth.$^{11-12}$ Furthermore, we observed that in the injured vessel wall there is increased ROS production. Antioxidants decrease neointimal VSMC proliferation and promote outward vessel remodelling in the pig coronary injury model.$^{13}$ We showed that many proteins kinases are involved in ROS mediated signalling and gene expression.$^{14-18}$ Recently we have demonstrated the novel finding that ROS stimulated VSMC synthesise and secrete proteins which may activate intracellular events in an autocrine and paracrine fashion.$^{19}$ In this article, we describe these factors, termed SOXF, for Secreted Oxidative stress induced Factors, which are potentially important mediators of the vessel wall response to ROS.

**Purification and identification of SOXF**

ROS stimulate VSMC growth and DNA synthesis$^{11}$ by activating signal cascades such as those involving the extracellular signal regulated kinases (ERK1/2).$^4$ We found that activation of ERK1/2 by O$_2^-$ generators such as the naphthoquinolinedione LY83583, menadione, and xanthine/xanthine oxidase was biphasic: an early peak of ERK1/2 activity was present at 5–10 minutes, whereas a delayed ERK1/2 activation appeared at two hours.$^{21}$ A similar biphasic activation of ERK1/2 has been reported for mitogens such as fibroblast growth factor.$^{22}$ One logical mechanism for endothelial cells and VSMC to respond to ROS would be to produce autocrine/paracrine signals that enhance cell survival or stimulate pathways that protect cells from the damaging effects of ROS. VSMC are particularly likely to secrete protective factors that also promote cell survival based on previous studies that demonstrate secretion of growth factors from VSMC in response to various stimuli.$^{23}$

To identify the presence of SOXF from VSMC stimulated by LY83583, the ability of conditioned medium to stimulate ERK1/2 was assayed. ERK1/2 activity, measured as a phospho-ERK1/2 specific antibody, demonstrated a significant increase with conditioned medium from VSMC treated with LY83583, but not in control cells. The activity was sensitive to trypsin (5 µg/ml for 30 minutes), and was inhibited by heating to 100°C, suggesting a protein factor or factors. We analysed the proteins released into the medium in response to LY83583, by $^{[35]}$S-methionine labelling. Approximately 35 protein bands were detected by autoradiography, suggesting that multiple proteins were released in response to LY83583.

To purify SOXF we used a sequential chromatographic approach that involved SP-Sepharose, heparin-Sepharose, phenyl Sepharose, and S-200 gel filtration chromatography.$^{19}$ For each step, activity was assayed for ERK1/2 stimulation by phospho-ERK1/2 Western blot using growth arrested VSMC. SOXF activity was associated with three protein peaks of approximate molecular weights 80–100 kD, > 20–30 kD, and > 45–65 kD, respectively (in order of relative ERK1/2 stimulating activity). Proteins were identified by tryptic digestions followed by mass spectrometry. The collision induced dissociation spectra were used to identify the proteins from which the peptide originated by database searching using the Sequest software program.$^{24,25}$

Unambiguous identification of proteins in the 90 kD band revealed heat shock protein 90-α (HSP90-α). Unambiguous identification of proteins in the 20 kD band revealed cyclophilin B (CyPB) and cyclophilin A (CyPA). No proteins were identified in the 56 kD and 27 kD bands. Other proteins identified included ezrin and moesin.

To prove that proteins identified as putative SOXF were released specifically from LY83583 treated VSMC, we compared the relative protein abundance of candidate SOXF proteins in the total cell lysate in conditioned medium, before and after LY83583 stimulation. Conditioned media from control and LY83583 treated cells were concentrated, then analysed by SDS-PAGE followed by Western blot analysis for HSP90 (with an antibody that recognises both HSP90-α and HSP90-β). The abundance of HSP90 was compared to two intracellular proteins of similar molecular weights; PKC-ζ (with an antibody which also recognizes PKC-α), and c-Raf-1. After treatment with LY83583 for two hour, there was a 10-fold increase in HSP90-α present in the conditioned medium, but no detectable HSP90-β, PKC or c-Raf-1. These results suggest that regulated secretion of HSP90-α occurred in response to LY83583.

**Abbreviations:** Ang II, angiotensin II; CyPA, cyclophilin A; ERK, extracellular regulated signal kinase; HSP90, heat shock protein 90; PDGF, platelet derived growth factor; PPIase, peptidyl-prolyl cis-trans isomerase; ROS, reactive oxygen species; SOXF, secreted oxidative stress induced factors; VSMC, vascular smooth muscle cells
To study the role of intracellular ROS in CyPA function, we studied cells transfected with nox1 (homolog of the NADPH oxidase catalytic subunit) to stimulate ROS production.16 CyPA expression and secretion were increased, and antioxidant blocked the secretion of CyPA from nox1-transfected cells.10

**FUNCTIONAL STUDIES OF SOXF**

To provide further evidence that HSP90-α and CyPA are SOXF, human recombinant HSP90-α (hrHSP90-α) and hrCyPA were purified and tested on VSMC cultures. Both CyPA and hrHSP90-α stimulated ERK1/2 activity in VSMC in a concentration dependent manner.15 20

To determine the physiological significance of SOXF, we studied the effects of hrCyPA on VSMC DNA synthesis: 10 nmol/l hrCyPA significantly stimulated DNA synthesis in VSMC (twofold increase versus 0.1% serum) assayed by [1H]thymidine incorporation.20 Thus, CyPA has growth promoting effects on VSMC which may contribute significantly to the growth promoting activity of ROS in VSMC. To further determine whether CyPA prevents VSMC apoptosis, we used sodium nitroprusside (SNP), which was shown to induce VSMC apoptosis.27 28 Incubating VSMC with 1 mmol/l SNP for 24 hours decreased cell viability to 19.4% of control, measured with a modified MTT assay. Addition of 10 nM hrCyPA in the presence of 1 mmol/l SNP blocked apoptosis, with cell viability returning to 47% of control.20 In response to 0.5 mmol/l SNP for 24 hours, 10% of VSMC were apoptotic as measured by nuclear morphology after DAPI staining, consistent with previous reports.27 28 Addition of hrCyPA significantly inhibited apoptosis induced by 0.5 mmol/l SNP with a decrease of 55%. These results indicated that SOXF have significant physiological effects on VSMC.

To study whether SOXF are involved in vascular lesion formation in vivo, we examined the expression of CyPA in balloon injured rat carotid arteries,29 since this model is associated with ROS generation, and neo-intima formation in injured vessels develops largely as a consequence of VSMC proliferation.29 30 Morphologic analysis demonstrated formation of a neo-intima within a week after injury. Immunoreactive CyPA was present at low level in sections of sham operated arteries. By 24 hours after balloon injury, abundant CyPA immunoreactivity was present throughout the vessel with particularly strong staining in the adventitia. By day 4, the majority of the CyPA staining was localised to the first cells forming the neo-intima and the most luminal medial VSMC layers. After one week of injury, when a substantial neo-intima had formed, CyPA immunoreactivity was highest in the neo-intima and most luminal medial VSMC. These findings show that CyPA expression is dramatically increased with a time course that paralleled neo-intima formation, suggesting an important role for CyPA in the cell response to oxidative stress induced by vascular injury.

**CONCLUSION**

In summary, our recent studies demonstrate that CyPA and HSP90 are secreted redox sensitive mediators. Because both cyclophilins and heat shock proteins act as chaperones, their secretion suggests an important role in the stress response to ROS in maintaining normal protein folding and function. The novel findings of our work suggest roles for HSP90 and CyPA as mediators themselves by promoting cell survival and growth. Understanding the mechanisms by which ROS stimulate gene expression and protein secretion should provide important insights into the cellular response to oxidative stress and new therapeutic targets for cardiovascular disease.

**ACKNOWLEDGMENTS**

This work was supported by grants from National Institutes of Health (HL44721 and HL49192 to BCB) and from American Heart Association (0235480T to ZJ).

**Authors’ affiliations**

Z G Jin, B C Berk, Center for Cardiovascular Research, University of Rochester, New York, USA

Correspondence to: Bradford C Berk, MD, PhD, University of Rochester, Department of Medicine, Box MED, Rochester, NY 14642, USA; bradford_berk@urmc.rochester.edu

**REFERENCES**

Coronary artery aneurysms are rare disorders defined by a vessel diameter ≥1.5 times the reference artery. Aneurysms can be characterised by abnormal dilatation of a localised or diffuse arterial segment. Potential complications associated with these abnormalities include thrombus formation and distal embolisation and, rarely, rupture. Until recently, the only alternative to medical treatment was surgical ligation of the aneurysm with distal bypass surgery. We report on the effectiveness of polytetrafluoroethylene (PTFE) covered stents in the treatment of two separate patients. In both cases the aneurysms were most likely caused by coronary artery atherosclerosis.

(A) 71 year old male, admitted for angina at rest. History of previous non-Q wave myocardial infarction. Coronary angiography showed a thrombus containing giant aneurysm of the left circumflex coronary artery as well as a >75% stenosis distal to the aneurysm. (B) Two PTFE covered stents (4.0×19 mm + 4.0×16 mm, GraftMaster Jostent, Jomed) were necessary to cover this large fusiform aneurysm completely. High pressure balloon post-dilation was performed with final TIMI 3 grade flow. The patient was pre-treated with glycoprotein IIb/IIIa inhibitors. Upon discharge, clopidogrel and aspirin treatment was started. The patient was well at three months follow up.

(A) 77 year old male, admitted for unstable angina. Coronary angiography revealed triple vessel coronary artery disease and a large saccular aneurysm of the proximal left anterior descending coronary artery. A 75% stenosis was present in the artery immediately proximal to the aneurysm. (B) Both stenosis and aneurysm were treated with a PTFE covered stent (3.0×16 mm, GraftMaster Jostent, Jomed). The covered stent completely closed the entrance of the aneurysm, and no contrast medium was seen entering the aneurysm in the final angiographic images. The first diagonal branch was occluded, causing a lateral myocardial infarction with creatine phosphokinase peak of 891 IU/l. The patient was discharged after six days, and treatment with aspirin and clopidogrel was begun.

doi: 10.1136/hrt.2003.022749
Polytetrafluoroethylene (PTFE) covered stents for the treatment of coronary artery aneurysms

M Fineschi, T Gori, G Sinicropi and A Bravi

*Heart* 2004 90: 490
doi: 10.1136/hrt.2003.022749

Updated information and services can be found at:
http://heart.bmj.com/content/90/5/490

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/